drugset
drugset / Trial / NCT05245994

An Open Label, Multicenter Phase 2 Study of Durvalumab (MEDI4736) + Olaparib as Maintenance Therapy in Chinese

NCT05245994 ↗

Phase 2 Unknown 60 enrolled Li Zhang, MD
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study was to evaluate the efficacy and safety of combining durvalumab with EP followed by durvalumab + olaparib maintenance therapy as first-line treatment in patients with extensive-disease small-cell lung cancer (SCLC).

Timeline

Start
2021-08-21
Primary completion
2023-05
Completion
2023-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Durvalumab Monoclonal antibody 1500 mg Intravenous
Subject Olaparib Small molecule 300 mg Oral
Background Carboplatin Small molecule 5 unknown Intravenous
Background Carboplatin Small molecule 6 unknown Intravenous
Background Cisplatin Other / unclassified 75 mg/m2 Intravenous
Background Cisplatin Other / unclassified 80 mg/m2 Intravenous
Background Etoposide Small molecule 80 mg/m2 Intravenous
Background Etoposide Small molecule 100 mg/m2 Intravenous

Indications

small cell lung carcinoma